Pari Mody draws from a background in science and law to counsel clients on legislative, regulatory, and legal matters related to healthcare and Food and Drug Administration regulated products, including pharmaceuticals, medical devices, foods, dietary supplements, and cosmetics.

Ms. Mody counsels a wide range of clients, including manufacturers, healthcare systems, trade associations, and nonprofit research foundations, on issues related to healthcare reform, Medicare coverage and reimbursement, Medicaid, health information technology, federal research funding, and the development, approval, and marketing of FDA-regulated products. She has extensive experience navigating the legislative and regulatory processes, drafting legislative language, preparing comment letters, and developing and implementing legislative and regulatory strategies for individual clients and coalitions. Ms. Mody frequently works with both congressional and agency-level staff to advocate on behalf of clients.

Prior to joining the firm, Ms. Mody was an associate at another international law firm and worked as a researcher at the Johns Hopkins University and the University of Pennsylvania.

Experience

  • Medical device manufacturer in securing Medicare coverage for the client's device, following a multi-year, coordinated congressional and agency effort.
  • Precision medicine biotech in reversing a potential 85% cut in Medicare payment for a molecular diagnostic test through a rapid-response Congressional, regulatory and coalition strategy.
  • Medical device supplier in preserving Medicare Part B coverage of home infusion pumps.
  • Pharmaceutical companies in a variety of legislative initiatives, including the reauthorization of the Prescription Drug User Fee Act and amendments to the Orphan Drug Act.
  • Research institute in securing a $21 million increase in appropriations to expand the Department of Veterans Affairs post-traumatic stress disorder research portfolio.
  • Two pro bono research and patient advocacy foundations in securing the introduction of bicameral, bipartisan legislation to authorize increased federal funding for research dedicated to a specific disease.

Perspectives

5 Health Care Policy Issues To Follow In 2018
Health Law360, Insurance Law360, Life Sciences Law360, and Public Policy Law360
FDA Releases Work Plan Implementing the 21st Century Cures Act
Advisory
GAO Aims to Increase Consumer Clarity Regarding the Regulation of Memory Supplement Advertising
Seller Beware: Consumer Protection Insights for Industry
FDA’s Policymaking and the Changing Compliance Landscape for ‘Healthy’ Foods
Seller Beware: Consumer Protection Insights for Industry
Obama Administration Continues to Push Food Policy Agenda
Seller Beware: Consumer Protection Insights for Industry
More

Recognition

Excellence in Advocacy Awards
Finalist, Excellence in a Federal Issue Campaign (2017)

Credentials

Education
  • JD, University of Maryland Francis King Carey School of Law, 2014, magna cum laude, Order of the Coif
  • BA, Oberlin College, 2006, high honors
Admissions
  • District of Columbia
  • Maryland
Activities
  • Member, American Health Lawyers Association
  • Member, Women in Government Relations
Overview

Email Disclaimer